FOI Request – Diagnosis of Alzheimer’s Disease
1. I would be grateful if you could send the Trust’s most recent planning document(s) for the diagnosis and treatment of Alzheimer’s Disease including implementation of lumbar punctures (CSF) and Blood-based Biomarker testing. Please include planning documents that cover the entire Trust and specific department plans, such as neurology, psychiatry, care of the elderly, pathology or memory clinic teams.
2. How many patients were diagnosed with Alzheimer’s Disease (ICD-10 codes = G30, G30.1, G30.8, G30.9, F00, F00.1, F00.2 or F00.9) in your Trust in the last 12-month period for which data are available?
3. How many patients were diagnosed with Mild Cognitive Impairment and / or Mild Dementia due to Alzheimer’s Disease (ICD-10 codes = G31.84, G30.1, or MMSE scores = 21 to 24) in your Trust in the last 12-month period for which data are available?
4. Where, if at all, does the Trust carry out lumbar punctures (cerebrospinal fluid) for diagnosing patients with Alzheimer’s Disease?
5. Please provide a list of the full names of other Trusts or other organisations to which the Trust refers patients for lumbar punctures in the diagnosis of Alzheimer’s Disease.
6. What is the average waiting time for a patient to get an appointment for a lumbar puncture to test for a diagnosis of Alzheimer’s Disease?
7. How many lumbar punctures to test for Alzheimer’s Disease took place in the last 3-month period for which data are available?
8. How many Blood-based Biomarker (BBBM) tests from Cerebrospinal fluid (CSF) to test for Alzheimer’s Disease were conducted in the last 3-month period for which data are available?
9. Where, if at all, does the Trust carry out Blood-based Biomarker (BBBM) tests from Cerebrospinal fluid (CSF) for diagnosing patients with Alzheimer’s Disease?
10. Please provide a list of the full names of other Trusts or other organisations, to which the Trust refers Blood-based Biomarker tests from cerebrospinal fluid (CSF) for pathology in the diagnosis of Alzheimer’s Disease.
11. What is the average waiting time for pathology results to come back from Blood-based Biomarker tests?
12. To what extent are there plans for service improvement of diagnosing Alzheimer’s Disease?
13. Are the plans for service improvement of diagnosing Alzheimer’s Disease related to:
Cognitive assessment services
Biomarker services
None / neither
14. Which of the following services does the Trust have in place in preparation for increased service delivery for Alzheimer’s Disease? Please complete the table provided.